Investigational drug · Phase 2
itacitinib
Also called: INCB039110
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-Cell Malignancies, Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
54
Any phase or sponsor naming "itacitinib"
First trial start
2016
Dec 20, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "itacitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-Cell Malignancies
- Lung Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "itacitinib" as an intervention, largest first.
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseasePivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03139604 · 439 participants · Start Jul 19, 2017 · Primary completion May 2, 2019
Drug: Itacitinib; Placebo and 2 more · For: Graft-versus-host Disease (GVHD)
Sites: La Jolla, California; Los Angeles, California; Stanford, California · 129 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
Incyte CorporationIncyte (INCY)
NCT02646748 · 159 participants · Start Jan 25, 2016 · Primary completion Nov 7, 2019
Drug: Pembrolizumab; itacitinib and 1 more · For: Colorectal Cancer (CRC); Endometrial Cancer; Melanoma and 8 more
Sites: San Francisco, California; Santa Monica, California; Washington D.C., District of Columbia · 17 sites in all
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePivotal-lookingTerminated
Incyte CorporationIncyte (INCY)
NCT03584516 · 155 participants · Start Jan 17, 2019 · Primary completion Nov 3, 2023
Drug: Itacitinib; Placebo and 2 more · For: Chronic Graft-versus-host Disease
Sites: Tucson, Arizona; Little Rock, Arkansas; Duarte, California · 133 sites in all
Incyte CorporationIncyte (INCY)
NCT02559492 · 142 participants · Start Nov 2015 · Primary completion Sep 10, 2018
Drug: Itacitinib; Epacadostat and 2 more · For: Solid Tumors
Sites: Duarte, California; Denver, Colorado; New Haven, Connecticut · 11 sites in all
Incyte CorporationIncyte (INCY)
NCT01905813 · 121 participants · Start Jun 30, 2013 · Primary completion Feb 26, 2026
Drug: INCB040093; INCB040093 + itacitinib · For: B-cell Malignancies
Sites: Birmingham, Alabama; Jacksonville, Florida; Ann Arbor, Michigan · 6 sites in all
- A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT04071366 · 112 participants · Start Feb 7, 2020 · Primary completion Feb 23, 2023
Drug: Itacitinib; Immune effector cell therapy and 2 more · For: Cytokine Release Syndrome
Sites: Miami, Florida; Tampa, Florida; Boston, Massachusetts · 10 sites in all
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruiting
Incyte CorporationIncyte (INCY)
NCT04509700 · 112 participants · Start Aug 3, 2020 · Primary completion Nov 5, 2026
Drug: Parsaclisib; parsaclisib + itacitinib and 2 more · For: B-Cell Malignancies
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 105 sites in all
- A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisPivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT01626573 · 106 participants · Start Mar 2012 · Primary completion Jul 2013
Drug: Itacitinib; Itacitinib Placebo · For: Rheumatoid Arthritis
Sites: Palm Desert, California; Pasadena, California; Lake Mary, Florida · 18 sites in all
Michael SavonaAcademic, hospital or other
NCT04061421 · 94 participants (planned) · Start Nov 24, 2021 · Primary completion Aug 2027
Drug: ASTX727; Itacitinib and 1 more · For: MDS/MPN
Sites: Tampa, Florida; Rochester, New York; Portland, Oregon · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma.
J Wagner M, D Cranmer L, T Loggers E, et al. · Oncoimmunology 2026
- Mechanical forces enable human stem cell modeling of protein aggregation cardiomyopathy.
Kooh YKG, Bahmani B, Zhao C, et al. · Sci Adv 2026
- Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results.
Shah NN, Choe H, Hardy NM, et al. · Bone Marrow Transplant 2026
- Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Krebs M, Gulyás L, Fazekas KK, et al. · J Eur Acad Dermatol Venereol 2026
- Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results.
Shah N, Choe H, Hardy N, et al. · Res Sq 2026
- Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?
Jamil MA, Otoukesh S, Ali H · Expert Opin Investig Drugs 2026
Also in development for B-Cell Malignancies
- EmavusertibCA-4948Phase 22 trials
Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
- parsaclisibINCB050465Phase 22 trials
Incyte · Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma, B-Cell Malignancies
- AZD5492Phase 21 trial
AstraZeneca · B-cell Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.